Table 2:

Summary of tumor grades, ⁶²Cu-ATSM uptake values, MR findings, and HIF-1α expression

Case No.	WHO Grade	⁶²Cu-ATSM			Enhancement on MRI	HIF-1α Expression^{^a}
Case No.	WHO Grade	SUV_max	SUV_mean ± SD	T/B Ratio	Enhancement on MRI	HIF-1α Expression^{^a}
1	III	0.51	0.38 ± 0.07	0.7	E	Negative
2	IV	4.33	1.79 ± 0.58	9.7	E+N	Positive
3	II	0.59	0.43 ± 0.10	0.7	None	Negative
4	III	0.92	0.59 ± 0.14	1.8	E	Positive
5	III	0.73	0.51 ± 0.09	2.3	E+N	Negative
6	IV	1.84	1.30 ± 0.21	2.5	E+N	Positive
7	III	1.02	0.73 ± 0.24	1.6	E	Negative
8	IV	1.15	0.76 ± 0.14	2.0	E+N	Positive
9	II	0.44	0.32 ± 0.07	1.0	E	Negative
10	III	1.01	0.58 ± 0.16	1.5	E	Negative
11	IV	2.04	1.29 ± 0.17	1.9	E+N	Positive
12	IV	1.17	0.84 ± 0.10	3.0	E+N	Positive
13	II	0.67	0.33 ± 0.09	1.3	E	Negative
14	IV	1.32	0.96 ± 0.09	4.3	E+N	Positive
15	IV	1.35	0.84 ± 0.19	1.9	E+N	Positive
16	II	1.59	0.80 ± 0.14	1.8	E	Positive
17	III	0.46	0.30 ± 0.05	0.4	E	Negative
18	IV	1.62	0.69 ± 0.17	1.5	E+N	Positive
19	III	1.46	0.80 ± 0.13	1.3	E	Negative
20	IV	1.54	0.77 ± 0.09	1.9	E+N	Positive
21	IV	1.82	0.91 ± 0.15	2.6	E+N	Positive
22	IV	0.94	0.68 ± 0.17	2.3	E+N	Positive

Note:—E indicates contrast enhancement without necrosis; E+N, contrast enhancement with necrosis; None, no enhancement; SUV_max, maximum standard uptake value; SUV_mean, mean standard uptake value.
↵a Negative indicates <5% HIF-1α-positive cells; positive indicates ≥5% HIF-1α-positive cells.